499 related articles for article (PubMed ID: 29381098)
21. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
Buhimschi AD; Armstrong HA; Toure M; Jaime-Figueroa S; Chen TL; Lehman AM; Woyach JA; Johnson AJ; Byrd JC; Crews CM
Biochemistry; 2018 Jul; 57(26):3564-3575. PubMed ID: 29851337
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
Zhang SQ; Smith SM; Zhang SY; Lynn Wang Y
Br J Haematol; 2015 Aug; 170(4):445-56. PubMed ID: 25858358
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies.
Lama TG; Kyung D; O'Brien S
Expert Rev Hematol; 2020 Aug; 13(8):871-883. PubMed ID: 32673127
[TBL] [Abstract][Full Text] [Related]
24. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.
Burger JA; Landau DA; Taylor-Weiner A; Bozic I; Zhang H; Sarosiek K; Wang L; Stewart C; Fan J; Hoellenriegel J; Sivina M; Dubuc AM; Fraser C; Han Y; Li S; Livak KJ; Zou L; Wan Y; Konoplev S; Sougnez C; Brown JR; Abruzzo LV; Carter SL; Keating MJ; Davids MS; Wierda WG; Cibulskis K; Zenz T; Werner L; Dal Cin P; Kharchencko P; Neuberg D; Kantarjian H; Lander E; Gabriel S; O'Brien S; Letai A; Weitz DA; Nowak MA; Getz G; Wu CJ
Nat Commun; 2016 May; 7():11589. PubMed ID: 27199251
[TBL] [Abstract][Full Text] [Related]
25. MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia.
Saba NS; Wong DH; Tanios G; Iyer JR; Lobelle-Rich P; Dadashian EL; Liu D; Fontan L; Flemington EK; Nichols CM; Underbayev C; Safah H; Melnick A; Wiestner A; Herman SEM
Cancer Res; 2017 Dec; 77(24):7038-7048. PubMed ID: 28993409
[TBL] [Abstract][Full Text] [Related]
26. Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.
Ayed AO; Parikh SA
Leuk Lymphoma; 2018 Oct; 59(10):2287-2296. PubMed ID: 29115892
[TBL] [Abstract][Full Text] [Related]
27. Ibrutinib treatment of CLL: the cancer fights back.
Young RM; Staudt LM
Cancer Cell; 2014 Jul; 26(1):11-3. PubMed ID: 25026208
[TBL] [Abstract][Full Text] [Related]
28. How I manage ibrutinib-refractory chronic lymphocytic leukemia.
Woyach JA
Blood; 2017 Mar; 129(10):1270-1274. PubMed ID: 28096090
[TBL] [Abstract][Full Text] [Related]
29. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
[TBL] [Abstract][Full Text] [Related]
30. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.
Guo A; Lu P; Galanina N; Nabhan C; Smith SM; Coleman M; Wang YL
Oncotarget; 2016 Jan; 7(4):4598-610. PubMed ID: 26717038
[TBL] [Abstract][Full Text] [Related]
31. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.
Landau DA; Sun C; Rosebrock D; Herman SEM; Fein J; Sivina M; Underbayev C; Liu D; Hoellenriegel J; Ravichandran S; Farooqui MZH; Zhang W; Cibulskis C; Zviran A; Neuberg DS; Livitz D; Bozic I; Leshchiner I; Getz G; Burger JA; Wiestner A; Wu CJ
Nat Commun; 2017 Dec; 8(1):2185. PubMed ID: 29259203
[TBL] [Abstract][Full Text] [Related]
32. Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.
Wu J; Zhang M; Liu D
Oncotarget; 2017 Jan; 8(4):7201-7207. PubMed ID: 27776353
[TBL] [Abstract][Full Text] [Related]
33. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
[TBL] [Abstract][Full Text] [Related]
34. B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy.
Woyach JA; Ghia P; Byrd JC; Ahn IE; Moreno C; O'Brien SM; Jones D; Cheung LWK; Chong E; Kwei K; Dean JP; James DF; Wiestner A
Clin Cancer Res; 2023 Aug; 29(16):3065-3073. PubMed ID: 37314786
[TBL] [Abstract][Full Text] [Related]
35. Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry.
Takács F; Kotmayer L; Czeti Á; Szalóki G; László T; Mikala G; Márk Á; Masszi A; Farkas P; Plander M; Weisinger J; Demeter J; Fekete S; Szerafin L; Deák BM; Szaleczky E; Sulák A; Borbényi Z; Barna G
Pathol Oncol Res; 2022; 28():1610659. PubMed ID: 36213161
[No Abstract] [Full Text] [Related]
36. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
Reiff SD; Mantel R; Smith LL; Greene JT; Muhowski EM; Fabian CA; Goettl VM; Tran M; Harrington BK; Rogers KA; Awan FT; Maddocks K; Andritsos L; Lehman AM; Sampath D; Lapalombella R; Eathiraj S; Abbadessa G; Schwartz B; Johnson AJ; Byrd JC; Woyach JA
Cancer Discov; 2018 Oct; 8(10):1300-1315. PubMed ID: 30093506
[TBL] [Abstract][Full Text] [Related]
37. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
Robinson HR; Qi J; Cook EM; Nichols C; Dadashian EL; Underbayev C; Herman SEM; Saba NS; Keyvanfar K; Sun C; Ahn IE; Baskar S; Rader C; Wiestner A
Blood; 2018 Aug; 132(5):521-532. PubMed ID: 29743179
[TBL] [Abstract][Full Text] [Related]
38. Targeting BTK through microRNA in chronic lymphocytic leukemia.
Bottoni A; Rizzotto L; Lai TH; Liu C; Smith LL; Mantel R; Reiff S; El-Gamal D; Larkin K; Johnson AJ; Lapalombella R; Lehman A; Plunkett W; Byrd JC; Blachly JS; Woyach JA; Sampath D
Blood; 2016 Dec; 128(26):3101-3112. PubMed ID: 27756747
[TBL] [Abstract][Full Text] [Related]
39. Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.
Smith CIE; Burger JA
Front Immunol; 2021; 12():689472. PubMed ID: 34177947
[TBL] [Abstract][Full Text] [Related]
40. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
